Literature DB >> 16497271

N-acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in human mesangial cells via up-regulation of cell cycle modulators.

Keizo Kanasaki1, Masakazu Haneda, Toshiro Sugimoto, Kazuyuki Shibuya, Motohide Isono, Keiji Isshiki, Shin-ichi Araki, Takashi Uzu, Atsunori Kashiwagi, Daisuke Koya.   

Abstract

N-Acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) was originally reported as a natural inhibitor of the proliferation of stem cells. To elucidate whether Ac-SDKP inhibits the proliferation of human mesangial cells, we examined the effect of Ac-SDKP on fetal calf serum (FCS)- or platelet-derived growth factor (PDGF)-BB-induced DNA synthesis and a cell proliferation. Ac-SDKP inhibited PDGF-BB- or FCS-induced DNA synthesis without cellular toxicity. The protein expression of p53 and p27kip1 was significantly increased by Ac-SDKP. Ac-SDKP also up-regulated the PDGF-BB-stimulated expression of p21cip1 and suppressed PDGF-BB-induced cyclin D1 expression. In p53 knock-out human mesangial cells made with small interference RNA, the protein expression of p21cip1 and p27kip1 was also decreased and the inhibitory effect of Ac-SDKP on mesangial proliferation was completely abolished. Ac-SDKP increased the stability of p53 protein as demonstrated by pulse-chase experiment. These results suggest that p53 is the key mediator of Ac-SDKP-induced inhibition of DNA synthesis through the up-regulation of cell cycle modulators, highlighting a potential effect of Ac-SDKP on various progressive renal diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16497271     DOI: 10.1016/j.bbrc.2006.02.019

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research.

Authors:  Tang-Dong Liao; Xiao-Ping Yang; Martin D'Ambrosio; Yanlu Zhang; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

Review 2.  Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?

Authors:  Kamal M Kassem; Sonal Vaid; Hongmei Peng; Sarah Sarkar; Nour-Eddine Rhaleb
Journal:  Can J Physiol Pharmacol       Date:  2019-03-09       Impact factor: 2.273

3.  A Small Peptide Ac-SDKP Inhibits Radiation-Induced Cardiomyopathy.

Authors:  Umesh C Sharma; Swati D Sonkawade; Joseph A Spernyak; Sandra Sexton; Juliane Nguyen; Suraj Dahal; Kristopher M Attwood; Anurag K Singh; Jop H van Berlo; Saraswati Pokharel
Journal:  Circ Heart Fail       Date:  2018-08       Impact factor: 8.790

4.  Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.

Authors:  Hongmei Peng; Oscar A Carretero; Tang-Dong Liao; Edward L Peterson; Nour-Eddine Rhaleb
Journal:  Hypertension       Date:  2007-02-05       Impact factor: 10.190

5.  Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage.

Authors:  Umesh Sharma; Nour-Eddine Rhaleb; Saraswati Pokharel; Pamela Harding; Saman Rasoul; Hongmei Peng; Oscar A Carretero
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-04       Impact factor: 4.733

6.  Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.

Authors:  Megumi Kanasaki; Takako Nagai; Munehiro Kitada; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2011-11-30

Review 7.  N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.

Authors:  Keizo Kanasaki; Takako Nagai; Kyoko Nitta; Munehiro Kitada; Daisuke Koya
Journal:  Front Pharmacol       Date:  2014-04-14       Impact factor: 5.810

8.  Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.

Authors:  Kyoko Nitta; Sen Shi; Takako Nagai; Megumi Kanasaki; Munehiro Kitada; Swayam Prakash Srivastava; Masakazu Haneda; Keizo Kanasaki; Daisuke Koya
Journal:  Biomed Res Int       Date:  2016-03-20       Impact factor: 3.411

9.  AcSDKP regulates cell proliferation through the PI3KCA/Akt signaling pathway.

Authors:  Ping Hu; Bin Li; Wenhua Zhang; Yijian Li; Guang Li; Xinnong Jiang; Joanna Wdzieczak-Bakala; Jianmiao Liu
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.